Dalfampridine and C-reactive protein increased - a phase IV clinical study of FDA data

Summary:

C-reactive protein increased is reported as a side effect among people who take Dalfampridine (dalfampridine), especially for people who are female, 50-59 old, also take Ocrevus, and have Primary progressive multiple sclerosis.

The phase IV clinical study analyzes which people have C-reactive protein increased when taking Dalfampridine. It is created by eHealthMe based on reports of 9,652 people who have side effects when taking Dalfampridine from the FDA, and is updated regularly.

What is Dalfampridine?

Dalfampridine has active ingredients of dalfampridine. eHealthMe is studying from 9,658 Dalfampridine users. Check the latest studies of Dalfampridine.

What is C-reactive protein increased?

C-reactive protein increased is found to be associated with 1,569 drugs and 2,281 conditions by eHealthMe. Check the latest studies of C-reactive protein increased.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 22, 2026

9,652 people reported to have side effects when taking Dalfampridine.
Among them, 16 people (0.17%) have C-reactive protein increased.

Could Dalfampridine cause C-reactive protein increased?

Among these 16 people:

What is the gender of people who have C-reactive protein increased when taking Dalfampridine? *

female: 100 %
male: 0.0 %

What is the age of people who have C-reactive protein increased when taking Dalfampridine? *

What are other drugs people take besides Dalfampridine? *

What are other side effects people have besides C-reactive protein increased? *

Fatigue (feeling of tiredness): 16 people, 100.00%
Weakness: 14 people, 87.50%
Headache (pain in head): 12 people, 75.00%
Fall: 10 people, 62.50%
Gait Disturbance: 9 people, 56.25%
Urinary Tract Infection: 9 people, 56.25%
Drug Ineffective: 7 people, 43.75%
Fluid Retention (an abnormal accumulation of fluid in the blood): 7 people, 43.75%
Joint Pain: 7 people, 43.75%
Monocyte Count Increased: 6 people, 37.50%

What are the existing conditions these people have? *

Secondary Progressive Multiple Sclerosis (a stage of ms which comes after relapsing remitting ms in many cases): 7 people, 43.75%
Primary Progressive Multiple Sclerosis (primary progressive inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 7 people, 43.75%
Sleep Disorder: 6 people, 37.50%
Muscle Spasticity (tight or stiff muscles and an inability to control those muscles): 6 people, 37.50%
Gait Disturbance: 6 people, 37.50%
Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 2 people, 12.50%
Bladder Disorder: 1 person, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Dalfampridine and have C-reactive protein increased?

- Check whether C-reactive protein increased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Dalfampridine:

Dalfampridine (9,658 reports)

Browse all side effects of Dalfampridine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with C-reactive protein increased:

C-reactive protein increased (1,569 drugs)

Browse all the conditions that are associated with C-reactive protein increased:

C-reactive protein increased (2,281 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on dalfampridine (the active ingredients of Dalfampridine) and Dalfampridine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.